Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

MLA

Zeuzem, Stefan, et al. “Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3.” The New England Journal of Medicine, vol. 370, no. 21, May 2014, pp. 1993–2001. EBSCOhost, https://doi.org/10.1056/NEJMoa1316145.

APA

Zeuzem, S., Dusheiko, G. M., Salupere, R., Mangia, A., Flisiak, R., Hyland, R. H., Illeperuma, A., Svarovskaia, E., Brainard, D. M., Symonds, W. T., Subramanian, G. M., McHutchison, J. G., Weiland, O., Reesink, H. W., Ferenci, P., Hézode, C., & Esteban, R. (2014). Sofosbuvir and ribavirin in HCV genotypes 2 and 3. The New England Journal of Medicine, 370(21), 1993–2001. https://doi.org/10.1056/NEJMoa1316145

Chicago

Zeuzem, Stefan, Geoffrey M Dusheiko, Riina Salupere, Alessandra Mangia, Robert Flisiak, Robert H Hyland, Ari Illeperuma, et al. 2014. “Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3.” The New England Journal of Medicine 370 (21): 1993–2001. doi:10.1056/NEJMoa1316145.